Antibody-drug conjugates (ADCs) are targeted therapies with the expectation of broadened
therapeutic window due to tumor-specific drug delivery. Recent approvals, including ADCs …

Antibody-drug conjugates (ADCs) are biopharmaceutical products where a monoclonal
antibody is linked to a biologically active drug (a small molecule) forming a conjugate. Since …

Aims We studied the pharmacokinetics and exposure–response relationships of the
brentuximab vedotin (BV) antibody–drug conjugate (ADC) and unconjugated monomethyl …

Background and Purpose Around 40–50% of diffuse large-B cell lymphoma (DLBCL)
patients suffer from refractory disease or relapse after R-CHOP first-line treatment. Many …

Therapeutic monoclonal antibodies (mAbs) have been a promising therapeutic approach for
several diseases and a wide variety of mAbs are being evaluated in clinical trials. To …

Tisotumab vedotin is an investigational antibody–drug conjugate (ADC) for treatment of solid
tumors expressing tissue factor with accelerated approval from the US Food and Drug …

Antibody–drug conjugates (ADCs) are important molecular entities in the treatment of
cancer. These conjugates combine the target specificity of monoclonal antibodies with the …

Over the past two decades, antibody-drug conjugates (ADCs) have emerged as a promising
class of drugs for cancer therapy and have expanded to nononcology fields such as …

The favorable benefit–risk profile of polatuzumab vedotin, as demonstrated in a pivotal
Phase Ib/II randomized study (GO29365; NCT02257567), coupled with the need for effective …

A Cox proportional hazard (CoxPH) model is conventionally used to assess exposure–
response (E–R), but its performance to uncover the ground truth when only one dose level of …